Deep Cholesterol Binding Sites on Mammalian Membrane Proteins
GPCRs Class A
[With residue numbers in the Ballesteros-Weinstein numbering system; Units of E, kcals/mol with molar concentration units]
E |
Donor | Acceptor | Local Residues (within 3 Å of a cholesterol –OH group) |
||||||
| 5-hydroxytryptamine receptor 1B,bound ergotamine, Human 4iar | |||||||||
| -6.5 | Chl | OH | Thr64 [1.47] | OG1 | Thr64 [1.47] | Ser99 [2.54] | |||
| 5-hydroxytryptamine receptor 1B, bound dihydroergotamine, Human 4iaq | |||||||||
| -6.3 | Chl | OH | Ser99 [2.54] | O | Thr64 [1.47] | Ser99 [2.54] | |||
| Chl | OH | Thr64 [1.47] | OG1 | ||||||
| -6.2 | Chl | OH | Thr64 [1.47] | OG1 | Thr60 [1.43] | Leu61 [1.44] | Thr64 [1.47] | ||
| -5.8 | Chl | OH | Thr64 [1.47] | OG1 | Thr60 [1.43] | Thr64 [1.47] | Ser99 [2.54] | ||
| 5-hydroxytryptamine receptor 2B, bound ergotamine, Human 4ib4 | |||||||||
| -6.0 | Chl | OH | Thr228 [5.49] | OG1 | Leu223 [5.45] | Phe227 [5.48] | Thr228 [5.49] | ||
| -5.9 | Chl | OH | Ala224 [5.46] | O | Ala224 [5.46] | Thr228 [5.49] | |||
| Chl | OH | Thr228 [5.49] | OG1 | Ala224 [5.46] | Thr228 [5.49] | ||||
| -5.5 | Chl | OH | Met63 [1.411] | O | Met63 [1.411] | ||||
| 5-hydroxytryptamine receptor 2B, Human 4nc3 | |||||||||
| -6.7 | Chl | OH | Thr228 [5.49] | OG1 | Ala224 [5.46] | Thr228 [5.49] | |||
| -5.7 | Chl | OH | Met63 [1.411] | O | Met63 [1.411] | ||||
| 5-hydroxytryptamine receptor 2B, bound LSD, Human 5tvn | |||||||||
| -5.5 | Chl | OH | Thr228 [5.49] | OG1 | Thr228 [5.49] | ||||
| Adenosine receptor A1, Human 5uen | |||||||||
| -5.8 | Ser246 [6.47] | OG | Chl | O | Leu242 [6.43] | Ser246 [6.47] | |||
| Adenosine receptor A1 with PSB36 [PDB resiudes renumbered], Human 5n2s | |||||||||
| -5.8 | Chl | OH | Ser246 [6.47] | OG | Ser246 [6.47] | Leu276 [7.40] | Asn280 [7.45] | Met283 [7.48] | |
| Adenosine receptor A2a, thermostable mutant, active-like, complex with agonist, Human 4uhr | |||||||||
| None | |||||||||
| Adenosine receptor A2a, thermostable mutant staR2, complex with antagonist, Human 3uza | |||||||||
| -5.8 | Chl | OH | Cys185 [5.461] | O | Gln89 [3.37] | Cys185 [5.461] | |||
| Adenosine receptor A2a, complex with inverse-agonist antibody and antagonist ZM241385, Human 3vg9 | |||||||||
| -5.9 | Chl | OH | Gly56 [2.54] | O | Gly56 [2.54] | Val57 [2.55] | |||
| Chl | OH | Val57 [2.55] | O | ||||||
| Adenosine receptor A2a, complex with antagonist ZM241385, Human 3vga | |||||||||
| None | |||||||||
| Adenosine receptor A2a, inactive state, with antagonist ZM241385, Human 3eml | |||||||||
| None | |||||||||
| Adenosine receptor A2a, thermostable mutant staR2, complex with caffeine, Human 3rfm | |||||||||
| None | |||||||||
| Adenosine receptor A2a, thermostable mutant staR2, inactive state, complex with XAC, Human 3rey | |||||||||
| None | |||||||||
| Adenosine receptor A2a, ithermostable mutant staR2, nactive state, with ZM241385, Human 3pwh | |||||||||
| None | |||||||||
| Adenosine receptor A2a, inactive state, with lipids and ZM241385, Human 4eiy | |||||||||
| None | |||||||||
| Adenosine receptor A2a, inactive state, with bound antagonist theophylline, Human 5k2a | |||||||||
| None | |||||||||
| Adenosine receptor A2a, inactive state, with bound antagonist theophylline, Human 5k2b | |||||||||
| None | |||||||||
| Adenosine receptor A2a, inactive state, with bound antagonist theophylline, Human 5k2c | |||||||||
| None | |||||||||
| Adenosine receptor A2a, inactive state, with bound antagonist theophylline, Human 5k2d | |||||||||
| None | |||||||||
| Adenosine receptor A2a, thermostable mutant staR2, inactive state, with bound antagonist theophylline, Human 5mzj | |||||||||
| -5.7 | Chl | OH | Gly56 [2.54] | O | Gly56 [2.54] | Val57 [2.55] | |||
| Chl | OH | Val57 [2.55] | O | ||||||
| Adenosine receptor A2a, thermostable mutant staR2, inactive state, with bound antagonist caffeine, Human 5mzp | |||||||||
| -5.6 | Chl | OH | Gly56 [2.54] | O | Gly56 [2.54] | Val57 [2.55] | |||
| Chl | OH | Val57 [2.55] | O | ||||||
| Adenosine receptor A2a, thermostable mutant staR2, inactive state, with bound antagonist PSB36, Human 5n2r | |||||||||
| None | |||||||||
| Adenosine receptor A2a,thermostable mutant staR2, inactive state, with bound antagonist ZMA, Human 5nlx | |||||||||
| None | |||||||||
| Adenosine receptor A2a, thermostable mutant staR2, inactive state, with bound antagonist ZMA, Human 5nm2 | |||||||||
| None | |||||||||
| Adenosine receptor A2a,thermostable mutant staR2, inactive state, with bound antagonist ZMA, Human 5nm4 | |||||||||
| None | |||||||||
| Adenosine receptor A2a,partially active state with agonist UK-432097, Human 3qak | |||||||||
| None | |||||||||
| Adenosine receptor A2a, thermostable mutant, partially active state with bound adenosine, Human 2ydo | |||||||||
| None | |||||||||
| Adenosine receptor A2a, thermostable mutant,partially active state with agonist NECA, Human 2ydv | |||||||||
| -5.5 | Chl | OH | Gly56 [2.54] | O | Gly56 [2.54] | Val57 [2.55] | |||
| Chl | OH | Val57 [2.55] | O | ||||||
| Adenosine receptor A2a, with G-alpha-S protein, Human 5g53 | |||||||||
| None | |||||||||
| Adenosine receptor A2a, with triazole-carboximidamide antagonist, Human 5uig | |||||||||
| -6.1 | Chl | OH | Gly56 [2.54] | O | Ala17 [1.43] | Gly56 [2.54] | Val57 [2.55] | ||
| Chl | OH | Val57 [2.55] | O | ||||||
| Adenosine receptor A2a,thermostable mutant, with antagonist, Human 6aqf | |||||||||
| -5.5 | Chl | OH | Val57 [2.55] | O | Gly56 [2.54] | Val57 [2.55] | |||
| Adenosine receptor A2a, thermostable mutant StaR2, inactive with lipid, Human 5o1g | |||||||||
| -5.8 | Chl | OH | Thr279 [7.44] | OG1 | Val275 [7.40] | Leu276 [7.41] | Thr279 [7.44] | ||
| -5.6 | Chl | OH | Gly56 [2.54] | O | Gly56 [2.54] | Val57 [2.55] | Pro61 [2.59] | ||
| Adenosine receptor A2a, thermostable mutant StaR2, inactive with lipid, Human 5o1h | |||||||||
| -5.8 | Chl | OH | Gly56 [2.54] | O | Gly56 [2.54] | Val57 [2.55] | Pro61 [2.59] | ||
| Chl | OH | Val57 [2.55] | O | ||||||
| -5.7 | Chl | OH | Thr279 [7.44] | OG1 | Val275 [7.40] | Leu276 [7.41] | Thr279 [7.44] | ||
| Adenosine receptor A2a, thermostable mutant StaR2, inactive with lipid, Human 5om1 | |||||||||
| -5.7 | Chl | OH | Gly56 [2.54] | O | Gly56 [2.54] | Val57 [2.55] | |||
| Chl | OH | Val57 [2.55] | O | ||||||
| Adenosine receptor A2a, thermostable mutant StaR2, inactive with lipid, Human 5om4 | |||||||||
| -5.7 | Chl | OH | Gly56 [2.54] | O | Gly56 [2.54] | Val57 [2.55] | |||
| Chl | OH | Val57 [2.55] | O | ||||||
| Adenosine receptor A2a, mylar structure, Human 5vra | |||||||||
| -6 | Chl | OH | Gly56 [2.54] | O | Gly56 [2.54] | Val57 [2.55] | |||
| Chl | OH | Val57 [2.55] | O | ||||||
| Angiotensin II receptor Type-1 (AT1) with bound antagonist, Human 4yay | |||||||||
| -5.6 | Chl | OH | Phe251 [6.46] | O | Phe251 [6.46] | ||||
| Angiotensin II receptor Type-1 (AT1) with bound inverse agonist olmesartan, Human 4zud | |||||||||
| -6.8 | Chl | OH | Ser252 [6.47] | OG | Phe248 [6.43] | Phe251 [6.46] | Ser252 [6.47] | ||
| Angiotensin II receptor Type-2 (AT2) active-like state, Human 5ung | |||||||||
| -6.6 | Chl | OH | Ser174 [4.56] | OG | Met170 [4.52] | Leu173 [4.55] | Ser174 [4.56] | ||
| Angiotensin II receptor Type-2 (AT2) active-like state, Human 5unf | |||||||||
| -7.1 | Chl | OH | Ser174 [4.56] | OG | Met170 [4.52] | Ser174 [4.56] | |||
| Angiotensin II receptor Type-2 (AT2) active-like state, Human 5unh | |||||||||
| -6.6 | Chl | OH | Ser174 [4.56] | OG | Met170 [4.52] | Leu173 [4.55] | Ser174 [4.56] | ||
| Beta-1 adrenergic receptor with bound dobutamine, Turkey 2y00 | |||||||||
| -6.1 | Chl | OH | Ile214 [5.45] | O | Glu130 [3.41] | Ile214 [5.45] | Pro219 [5.50] | ||
| Beta-1 adrenergic receptor with bound dobutamine, Turkey 2y01 | |||||||||
| -6.7 | Chl | OH | Leu171 [4.55] | O | Ala170 [4.54] | Leu171 [4.55] | Leu175 [4.59] | ||
| -6.3 | Chl | OH | Leu171 [4.55] | O | Ala170 [4.54] | Leu171 [4.55] | Phe174 [4.58] | Leu175 [4.59] | |
| -5.6 | Chl | OH | Ile214 [5.45] | O | Glu130 [3.41] | Ile214 [5.45] | Pro219 [5.50] | ||
| Beta-1 adrenergic receptor with bound carmoterol, Turkey 2y02 | |||||||||
| -6.7 | Chl | OH | Leu171 [4.55] | O | Ala170 [4.54] | Leu171 [4.55] | Leu175 [4.59] | ||
| -6.3 | Chl | OH | Leu171 [4.55] | O | Ala170 [4.54] | Leu171 [4.55] | Phe174 [4.58] | Leu175 [4.59] | |
| -5.8 | Chl | OH | Ile214 [5.45] | O | Glu130 [3.41] | Ile214 [5.45] | |||
| -5.5 | Chl | OH | Glu130 [3.41] | OE2 | Glu130 [3.41] | Ile214 [5.45] | Pro219 [5.50] | ||
| Chl | OH | Ile214 [5.45] | O | ||||||
| Beta-1 adrenergic receptor with bound isoprenaline, Turkey 2y03 | |||||||||
| -5.7 | Chl | OH | Glu130 [3.41] | OE2 | Glu130 [3.41] | Ile214 [5.45] | |||
| Chl | OH | Ile214 [5.45] | O | ||||||
| Beta-1 adrenergic receptor with bound salbutamol, Turkey 2y04 | |||||||||
| -5.9 | Chl | OH | Ile214 [5.45] | O | Glu130 [3.41] | Ile214 [5.45] | |||
| -5.8 | Chl | OH | Leu171 [4.55] | O | Ala170 [4.54] | Leu175 [4.59] | |||
| Beta-1 adrenergic receptor, with bound carazolol, Turkey 2ycw | |||||||||
| -5.6 | Chl | OH | Glu130 [3.41] | OE2 | Glu130 [3.41] | Ile214 [5.45] | |||
| Chl | OH | Ile214 [5.45] | O | ||||||
| Beta-1 adrenergic receptor, with bound cyanopindolol, Turkey 2ycx | |||||||||
| -5.7 | Chl | OH | Glu130 [3.41] | OE2 | Glu130 [3.41] | Ile214 [5.45] | |||
| Chl | OH | Ile214 [5.45] | O | ||||||
| Beta-1 adrenergic receptor, with bound cyanopindolol, Turkey 2ycy | |||||||||
| None | |||||||||
| Beta-1 adrenergic receptor, with bound iodoctanopindolol, Turkey 2ycz | |||||||||
| -5.8 | Chl | OH | Glu130 [3.41] | OE2 | Glu130 [3.41] | Ile214 [5.45] | |||
| Chl | OH | Ile214 [5.45] | O | ||||||
| -5.6 | Chl | OH | Ile214 [5.45] | O | Glu130 [3.41] | Ile214 [5.45] | Pro219 [5.50] | ||
| Beta-1 adrenergic receptor, basal state, Turkey 4gpo | |||||||||
| -5.5 | Chl | OH | Glu130 [3.41] | OE2 | Glu130 [3.41] | Ile214 [5.45] | |||
| Chl | OH | Ile214 [5.45] | O | ||||||
| Beta-1 adrenergic receptor, inactive, engineered, Turkey 2vt4 | |||||||||
| -5.8 | Chl | OH | Ile214 [5.45] | O | Glu130 [3.41] | Ile214 [5.45] | |||
| Beta-1 adrenergic receptor, engineered, with bound carvedilol, Turkey 4amj | |||||||||
| -5.6 | Chl | OH | Glu130 [3.41] | OE2 | Glu130 [3.41] | Ile214 [5.45] | Pro219 [5.50] | ||
| Chl | OH | Ile214 [5.45] | O | ||||||
| Beta-1 adrenergic receptor, engineered, with bound bucindolol, Turkey 4ami | |||||||||
| -6.1 | Chl | OH | Glu130 [3.41] | OE2 | Glu130 [3.41] | Ile214 [5.45] | |||
| Beta-1 adrenergic receptor, engineered, with inverse agonist, Turkey 5a8e | |||||||||
| -6.7 | Chl | OH | Ser169 [4.53] | OG | Val165 [4.49] | Ile168 [4.52] | Ser169 [4.53] | ||
| Beta-2 adrenergic receptor, active state, complex with antibody, Human 3p0g | |||||||||
| -6.2 | Chl | OH | Glu122 [3.41] | OE1 | Glu122 [3.41] | Val206 [5.46] | |||
| Chl | OH | Glu122 [3.41] | OE2 | ||||||
| Chl | OH | Val206 [5.46] | O | ||||||
| Beta-2 adrenergic receptor, active state, complex with G-protein, Human 3sn6 | |||||||||
| -5.8 | Chl | OH | Glu122 [3.41] | OE2 | Glu122 [3.41] | Val206 [5.46] | |||
| Chl | OH | Val206 [5.46] | O | ||||||
| -5.4 | Chl | OH | Glu122 [3.41] | OE2 | Glu122 [3.41] | ||||
| Beta-2 adrenergic receptor, agonist bound. Human 3pds | |||||||||
| -5.6 | Chl | OH | Glu122 [3.41] | OE2 | Glu122 [3.41] | Val206 [5.46] | |||
| Chl | OH | Val206 [5.46] | O | ||||||
| Beta-2 adrenergic receptor, inactive state, Human 3d4s | |||||||||
| -7.1 | Chl | OH | Gly320 [7.47] | O | Val317 [7.43] | Gly320 [7.47] | Phe321 [7.48] | ||
| -6.1 | Chl | OH | Ser161 [4.53] | OG | Val157 [4.49] | Ser161 [4.53] | |||
| Beta-2 adrenergic receptor, inactive state, Human 2rh1 | |||||||||
| -6.7 | Chl | OH | Gly320 [7.47] | O | Val317 [7.43] | Gly320 [7.47] | phe321 [7.48] | ||
| -5.8 | Chl | OH | Gly320 [7.47] | O | Val317 [7.43] | Gly320 [7.47] | |||
| Beta-2 adrenergic receptor,with allosteric antagonist, Human 5x7d | |||||||||
| -6.0 | Chl | OH | Thr164 [4.56] | OG1 | Val160 [4.52] | Leu163 [4.55] | Thr164 [4.56] | ||
| C5a anaphylatoxin chemotactic receptor 1, Human 5o9h | |||||||||
| None | |||||||||
| C-C chemokine receptor type 2, Human 5t1a | |||||||||
| -5.9 | Chl | OH | Thr296 [7.43] | OG1 | Thr296 7.43] | Cys299 [7.47] | |||
| C-C chemokine receptor type 5 with bound Maraviroc Human 4mbs | |||||||||
| None | |||||||||
| C-C chemokine receptor type 9 with vercirnon, Human 5lwe | |||||||||
| None | |||||||||
| C-X-C chemokine receptor type 4, complex with vMIP-II, Human 4rws | |||||||||
| -6.9 | Chl | OH | Cys251 [6.47] | O | Cys251 [6.47] | Thr287 [7.37] | Leu290 [7.40] | Ala291 [7.41] | |
| -6.4 | Chl | OH | Ala250 [6.46] | O | Ala250 [6.46] | Cys251 [6.47] | |||
| Chl | OH | Cys251 [6.47] | O | ||||||
| -6.0 | Chl | OH | Leu208 [5.47] | O | Leu208 [5.47] | Ile209 [5.48] | Gly212 [5.51] | ||
| C-X-C chemokine receptor type 4, inactive, with peptide antagonist CVX15, Human 3oe0 | |||||||||
| -7.1 | Chl | OH | Cys251 [6.47] | O | Cys251 [6.47] | Thr287 [7.37] | Leu290 [7.40] | Ala291 [7.41] | |
| -6.9 | Chl | OH | Ala250 [6.46] | O | Ala250 [6.46] | Cys251 [6.47] | Pro254 [6.50] | ||
| Chl | OH | Cys251 [6.47] | O | ||||||
| -6.3 | Chl | OH | Cys251 [6.47] | O | Cys251 [6.47] | Leu290 [7.40] | Ala291 [7.41] | ||
| -6.1 | Chl | OH | Gly159 [4.48] | O | Gly159 [4.48] | Val160 [4.49] | |||
| C-X-C chemokine receptor type 4, inactive, with IT1t antagonist, Human 3oe6 | |||||||||
| -6.0 | Chl | OH | Cys251 [6.47] | O | Cys251 [6.47] | Leu290 [7.40] | Ala291 [7.41] | ||
| -5.7 | Chl | OH | Cys251 [6.47] | O | Ala250 [6.46] | Cys251 [6.47] | Pro254 [6.50] | ||
| C-X-C chemokine receptor type 4, with IT1t antagonist, Human 3odu | |||||||||
| -6.8 | Chl | OH | Thr168 [4.57] | OG1 | Leu165 [4.54] | Thr168 [4.57] | Ile169 [4.59] | ||
| -6.8 | Chl | OH | Cys251 [6.47] | O | Ala250 [6.46] | Cys251 [6.47] | |||
| -6.7 | Chl | OH | Cys251 [6.47] | O | Cys251 [6.47] | Leu290 [7.40] | Ala291 [7.41] | ||
| -6.3 | Chl | OH | Cys251 [6.47] | O | Ala250 [6.46] | Cys251 [6.47] | Pro254 [6.50] | ||
| C-X-C chemokine receptor type 4, with IT1t antagonist, Human 3oe8 | |||||||||
| None | |||||||||
| C-X-C chemokine receptor type 4 , with IT1t antagonist, Human 3oe9 | |||||||||
| -6.2 | Chl | OH | Cys251 [6.47] | O | Cys251 [6.47] | Leu290 [7.40] | Ala291 [7.41] | ||
| -6.2 | Chl | OH | Leu86 [2.52] | O | Leu86 [2.52] | Thr90 [2.56] | Ile115 [3.31] | ||
| Cannabinoid receptor 1, complex with antagonist AM6538, Human 5tgz | |||||||||
| -6.2 | Chl | OH | Ser284 [5.48] | OG | Val283 [5.47] | Ser284 [5.48] | |||
| -5.7 | Chl | OH | Thr391 [7.47] | OG1 | Thr391 [7.47] | ||||
| Cannabinoid receptor 1, with bound inhibitor taranabant, Human 5u09 | |||||||||
| -6.5 | Chl | OH | Ser284 [5.48] | OG | Thr283 [5.47] | Ser284 [5.48] | |||
| Cannabinoid receptor 1, with bound agonist, Human 5xr8 | |||||||||
| -7.3 | Chl | OH | Ser199 [3.35] | OG | Gly195 [3.31] | Ala198 [3.34] | Ser199 [3.35] | ||
| -6.3 | Chl | OH | Thr128 [1.44] | OG1 | Gly127 [1.43] | Thr128 [1.44] | |||
| Cannabinoid receptor 1, with bound agonist, Human 5xra | |||||||||
| -7.5 | Chl | OH | Thr128 [1.44] | OG1 | Leu124 [1.40] | Thr128 [1.44] | |||
| -6.7 | Chl | OH | Ser199 [3.35] | OG | Gly195 [3.31] | Ala198 [3.34] | Ser199 [3.35] | ||
| Dopamine D2 receptor complex with risperidone,Human, 6c38 | |||||||||
| None | |||||||||
| Dopamine D3 receptor complex with antagonist, Human 3pbl | |||||||||
| None | |||||||||
| Dopamine D4 receptor complex with nemonapride, Human 5wiu | |||||||||
| -7.2 | Chl | OH | Thr159 [4.49] | OG1 | Phe124 [3.41] | Thr159 [4.49] | |||
| Dopamine D4 receptor Na-bound complex with nemonapride, Human 5wiv | |||||||||
| -6.1 | Chl | OH | Thr159 [4.49] | OG1 | Phe124. [3.41] | Thr159 4.49] | |||
| -6.1 | Chl | OH | Phe202 [5.48] | O | Phe202 [5.48] | ||||
| -5.7 | Chl | OH | Thr408 [6.49] | OG1 | Leu404 [6.45] | Thr408 [6.49] | |||
| Endothelin B receptor without bound endothelin-1, Human 5gli | |||||||||
| None | |||||||||
| Endothelin B receptorwith antagonist, Human 5x93 | |||||||||
| None | |||||||||
| Endothelin B receptor, with bound endothelin-1, Human 5glh | |||||||||
| -5.6 | Chl | OH | Ser279 [5.45] | OG | Ser279 [5.45] | Phe280 [5.46] | |||
| Free fatty acid receptor 1 GPR40 [PDB residues renumbered], Human 4phu | |||||||||
| -5.5 | Chl | OH | Leu235 [6.461] | O | Leu235 [6.461] | Cys2236 [6.47] | |||
| Histamine H1 receptor, complex with doxepin, Human 3rze | |||||||||
| -7.0 | Chl | OH | Leu154 [4.52] | O | Leu154 [4.52] | Trp158 [4.57] | Asn198 [5.461] | ||
| Leukotriene BLT1 receptor, Guinea Pig 5x33 | |||||||||
| -6.1 | Chl | OH | Ser278 [7.46] | OG | Leu275 [7.43] | Ser278 [7.46] | |||
| -6.0 | Chl | OH | Ser102 [3.37] | OG | Ile98 [3.33] | Ser102 [3.37] | |||
| Lysophosphatidic acid receptor 1 complex with ONO-9780307, Human 4z34 | |||||||||
| -6.2 | Chl | OH | Thr173 [4.51] | OG1 | Val169 [4.47] | Trp172 [4.50] | Thr173 [4.51] | ||
| Lysophosphatidic acid receptor 1 complex with ONO-9910539, Human 4z35 | |||||||||
| -6.2 | Chl | OH | Thr173 [4.51] | OG1 | Val169 [4.47] | Trp172 [4.50] | Thr173 [4.51] | ||
| Lysophosphatidic acid receptor 1 complex with ONO-3080573, Human 4z36 | |||||||||
| -6.2 | Chl | OH | Thr173 [4.51] | OG1 | Val169 [4.47] | Trp172 [4.50] | Thr173 [4.51] | ||
| Muscarinic acetylcholine receptor M1 with bound tiotropium, Human 5cxv | |||||||||
| -7.1 | Chl | OH | Ser36 [1.43] | OG | Ser36 [1.43] | Gly75 [2.54] | Thr76 [2.55] | Asn80 2.58] | |
| -5.7 | Chl | OH | Ala195 [5.46] | O | Gln110 [3.37] | Ala195 [5.46] | Ala196 [5.461] | ||
| Chl | OH | Ala196 [5.461] | O | ||||||
| Muscarinic acetylcholine receptor M2 with bound agonist iperoxo, Human 4mqs | |||||||||
| -7.6 | Chl | OH | Ser32 [1.41] | OG | Leu28 [1.37] | Ser32 [1.41] | |||
| -7.1 | Chl | OH | Ser32 [1.41] | OG | Leu28 [1.37] | Gly31 [1.40] | Ser32 [1.41] | ||
| Muscarinic acetylcholine receptor M2 with bound antagonist, Human 3uon | |||||||||
| -7.1 | Chl | OH | Ser34 [1.43] | OG | Ser34 [1.43] | Asn78 [2.58] | |||
| -6.8 | Chl | OH | Ser32 [1.41] | OG | Leu28 [1.37] | Gly31 [1.40] | Ser32 [1.41] | ||
| -6.3 | Chl | OH | Ser34 [1.43] | OG | Ser34 [1.43] | Ile38 [1.47] | Gly73 [2.54] | Val74 [2.55] | Asn78 [2.58] |
| Muscarinic acetylcholine receptor M3, lysozume fusion, with bound tiotropium, Rat 4daj | |||||||||
| -6.9 | Chl | OH | Gly117 [2.54] | O | Ala78 [1.43] | Gly117 [2.54] | Asn122 [2.58] | ||
| -5.7 | Chl | OH | Ala238 [5.461] | O | Asn152 [3.37] | Val155 [3.40] | Ala238 [5.461] | ||
| Muscarinic acetylcholine receptor M3, lysozyme fusion, with bound tiotropium, Rat 4u15 | |||||||||
| -6.8 | Trp199 [4.57] | NE1 | Chl | O | Asn152 [3.37] | Trp199 [4.57] | Ala238 [5.461] | ||
| -6.1 | Chl | OH | Thr504 [6.49] | OG1 | Ile500 [6.45] | Thr504 [6.49] | |||
| Muscarinic acetylcholine receptor M4 with bound tiotropium, Human 5dsg | |||||||||
| -7.5 | Chl | OH | Ser43 [1.43] | OG | Ser43 [1.43] | Asn87 [2.58] | |||
| -6.8 | Chl | OH | Ser41 [1.41] | OG | Thr37 [1.37] | Gly40 [1.40] | Ser41 [1.41] | ||
| -6.0 | Chl | OH | Ala203 [5.461] | O | Asn117 [3.37] | Ala203 [5.461] | |||
| Neurotensin receptor type 1,complex with neurotensin, Rat 4grv | |||||||||
| None | |||||||||
| Neurotensin receptor type 1,agonist bound, Rat 4buo | |||||||||
| None | |||||||||
| Neurotensin receptor type 1, mutant, Rat 3zev | |||||||||
| None | |||||||||
| Neurotensin receptor type 1, mutant, Rat 4bv0 | |||||||||
| None | |||||||||
| Neurotensin receptor type 1, engineered, Rat 4xee | |||||||||
| None | |||||||||
| Neurotensin receptor type 1, engineered, Rat 4xes | |||||||||
| -5.5 | Cys152 [3.35] | SG | Chl | O | Leu148 [3.31] | Ala151 [3.34] | Cys152 [3.35] | ||
| Neurotensin receptor type 1, constitutively active mutant, Rat 5t04 | |||||||||
| -7.7 | Chl | OH | Ser197 [4.53] | OG | Trp194 [4.50] | Ser197 [4.53] | Ala198 [4.54] | ||
| Nociceptin (NOP)receptor with bound C-35, Human 5dhg | |||||||||
| -5.8 | Chl | OH | Ser179 [4.54] | OG | Trp175 [4.50] | Ala176 [4.51] | Ser179 [4.54] | ||
| Nociceptin (NOP)receptor, engineered, with bound C-35, Human 5dhh | |||||||||
| -6.1 | Chl | OH | Tyr132 [3.34] | OH | Tyr132 [3.34] | Ser179 [4.54] | |||
| Nociceptin (NOP)receptor with bound peptide, Human 4ea3 | |||||||||
| -5.9 | Chl | OH | Ser179 [4.54] | OG | Trp175 [4.50] | Ser179 [4.54] | |||
| Opioid delta receptor comples with naltrindol, Mouse 4ej4 | |||||||||
| -6.8 | Chl | OH | Ser312 [7.47] | OG | Ala309 [7.43] | Ser312 [7.47] | Leu313 [7.48] | ||
| -6.1 | Chl | OH | Tyr130 [3.34] | OH | Tyr130 [3.34] | Ser177 [4.54] | |||
| Opioid delta receptor, complex with naltrindol, Human 4n6h | |||||||||
| None | |||||||||
| Opioid delta receptor, complex with tetrapeptide DIPP-NH2, Human 4rwd | |||||||||
| -6.0 | Chl | OH | Tyr130 [3.34] | OH | Tyr130 [3.34] | Ser177 [4.54] | |||
| Opioid delta receptor, complex with tetrapeptide DIPP-NH2, Human 4rwa | |||||||||
| -6.2 | Chl | OH | Tyr130 [3.34] | OH | Tyr130 [3.34] | Ser177 [4.54] | |||
| Opioid kappa receptor complex with JDTic, Human 4djh | |||||||||
| -7.3 | Chl | OH | Tyr140 [3.34] | OH | Tyr140 [3.34] | Trp183 [4.50] | Ser187 [4.54] | ||
| -6.8 | Chl | OH | Ser324 [7.47] | O | Ser324 [7.47] | Leu325 [7.48] | |||
| -6.4 | Chl | OH | Ser188 [4.55] | OG | Leu184 [4.51] | Ser188 [4.55] | |||
| -6.3 | Ser188 [4.55] | OG | Chl | O | Leu185 [4.52] | Ser188 [4.55] | |||
| -6.2 | Chl | OH | Ser324 [7.47] | O | Thr321 [7.43] | Ser324 [7.47] | Leu325 [7.48] | ||
| Opioid kappa receptor, Human 6b73 | |||||||||
| -7.8 | Chl | OH | Ser188 [4.55] | OG | Leu184 [4.51] | Ser187 [4.54] | Ser188 [4.55] | ||
| -7.7 | Chl | OH | Ser187 [4.54] | OG | Leu184 [4.51] | Ser187 [4.54] | Ser188 [4.55] | ||
| Opioid mu receptor, a dimer, complex with morphinan antagonist, Mouse 4dkl | |||||||||
| -6.7 | Chl | OH | Tyr149 [3.34] | OH | Tyr149 [3.34] | Ser196 [4.54] | |||
| -5.8 | Chl | OH | Ser119 [2.55] | OG | Ala115 [2.51] | Leu116 [2.52] | Ser119 [2.55] | ||
| Opioid mu receptor, bound to agonist BU72, Mouse 5c1m | |||||||||
| -6.6 | Chl | OH | Thr153 [3.38] | OG1 | Tyr149 [3.34] | Asn150 [3.35] | Thr153 [3.38] | ||
| -5.9 | Chl | OH | Thr327 [7.44] | OG1 | Ala323 [7.40] | Leu324 [7.41] | Thr327 [7.44] | ||
| Orexin receptor type 1, Human 4zjc | |||||||||
| None | |||||||||
| Orexin receptor type 2, Human, 4s0v | |||||||||
| None | |||||||||
| Orexin receptor type 2 plus antagonist, Human, 5wqc | |||||||||
| None | |||||||||
| Orexin receptor type 2 plus antagonist, Human, 5ws3 | |||||||||
| None | |||||||||
| P2Y purinoceptor 1,complex with BPTU, Human 4xnv | |||||||||
| -6.2 | Chl | OH | Ser272 [6.47] | OG | Ser272 [6.47] | Asn316 [7.45] | |||
| P2Y purinoceptor 1, complex with MRS2500, Human 4xnw | |||||||||
| None | |||||||||
| P2Y purinoceptor 12, complex with antithrombotic drug, Human 4ntj | |||||||||
| -7.2 | Chl | OH | Leu75 [2.55] | O | Leu72 [2.52] | Leu75 [2.55] | Thr76 [2.56] | ||
| Chl | OH | Thr76 [2.56] | OG1 | ||||||
| -6.9 | Chl | OH | Ser113 [3.41] | OG | Ser113 [3.41] | Asn201 [5.50] | |||
| -6.3 | Chl | OH | Thr76 [2.56] | OG1 | Leu72 [2.52] | Thr76 [2.56] | Ile103 [3.31] | ||
| P2Y purinoceptor 12, complex with bound agonist 2MeSADP, Human 4pxz | |||||||||
| -7.1 | Chl | OH | Leu72 [2.52] | O | Leu72 [2.52] | Thr76 [2.56] | |||
| Chl | OH | Thr76 [2.56] | OG1 | ||||||
| -7.1 | Chl | OH | Leu72 [2.52] | O | Leu72 [2.52] | Leu75 [2.55] | Thr76 [2.56] | ||
| Chl | OH | Thr76 [2.56] | OG1 | ||||||
| -5.5 | Chl | OH | Leu75 [2.55] | O | Leu75 [2.55] | Thr76 [2.56] | |||
| Chl | OH | Thr76 [2.56] | OG1 | ||||||
| Sphingosine 1-phosphate (S1P) receptor 1, Human 3v2y | |||||||||
| -7.0 | Chl | OH | Ser216 [2.53] | OG | Leu212 [5.49] | Ser216 [2.53] | |||
| -6.6 | Chl | OH | Thr211 [5.48] | OG1 | Thr208 [5.45] | Thr211 [5.48] | Leu212 [5.49] | ||
| -6.3 | Chl | OH | Glu62 [1.49] | OE1 | Phe58 [1.45] | Glu62 [1.49] | Gly305 [7.47] | ||
| Thrombin (proteinase-activated) receptor 1, PAR1 with antagonist vorapaxar, Human 3vw7 | |||||||||
| -5.5 | Chl | OH | Leu150 [2.52] | O | Leu150 [2.52] | Phe151 [2.53] | |||
| Viral GPCR US28, complex with fractalkine, Human herpesvirus 4xt3 | |||||||||
| None | |||||||||
| Viral GPCR US28, complex with fractalkine and nanobody, Human herpesvirus 4xt1 | |||||||||
| -5.7 | Chl | OH | Glu191 [5.41] | OE2 | Glu191 [5.41] | Leu194 [5.44] | Gly195 [5.45] | ||